|

Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment

RECRUITINGSponsored by UNC Lineberger Comprehensive Cancer Center
Actively Recruiting
SponsorUNC Lineberger Comprehensive Cancer Center
Started2024-05-03
Est. completion2027-01-15
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT04743674

Summary

The purpose of this study is to determine if ctHPVDNA (circulating tumor HPV DNA) can be used as a non-invasive biomarker for identification and treatment monitoring of cervical cancer by characterizing correlation between plasma ctHPVDNA, urine transrenal HPVDNA (TrHPVDNA) levels and presence of cervical cancer at diagnosis and following definitive intent management.

Eligibility

Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* 18 years of age or older on day of signing informed consent
* New diagnosis of cervical cancer
* Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee

Exclusion Criteria:

* Women who are pregnant

Conditions2

CancerCervical Cancer

Locations1 site

Melissa Knutsen
Chapel Hill, North Carolina, 27599
Melissa Knutsen919-445-4869melissa_knutsen@med.unc.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.